{name}
{subtitle}
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
city
~54 mi. (Sainte-Foy, Canada, +126 more cities)
facility
Research Site
biomarker
ER Positive, +2 more biomarkers
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~55 mi. (Lévis, Canada, +156 more cities)
facility
CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 218887
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~56 mi. (Québec, Canada, +89 more cities)
facility
Hopital Du Saint-Sacrement ( Site 0109)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~56 mi. (Québec, Canada, +454 more cities)
facility
CHA Hopital L'Enfant-Jesus
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~56 mi. (Québec, Canada, +262 more cities)
facility
Hopital du Saint Sacrement
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type